Springbok Analytics has completed an oversubscribed $5 million Series A funding round for its AI-powered muscle scanning technology. The FDA-cleared technology analyzes MRI scans to provide automated muscle health assessments, catering to the needs of athletes and individuals focused on longevity.
Springbok Analytics is focused on three key areas, demonstrating investor enthusiasm for life sciences, elite sports, and longevity solutions. The company offers three rapid MRI scan options: lower extremity, core, and full body. Imaging times range from 10 to 35 minutes. After the scan, Springbok’s AI software processes images, reviews them for quality, and generates a personalized report with 3D muscle visualizations and data, including analysis of tendons, bones, scar tissue, and edema. Reports are typically available within 1-2 business days.
Springbok recommends an annual scan in conjunction with a standard physical check-up to provide actionable insights for muscle health management, provided there are no existing injuries or conditions. Elite athletes may undergo 3-4 scans or more per year for injury rehabilitation or post-surgery recovery. These insights help trainers and coaches optimize performance and recovery.
Transition Equity Partners, LLC (TEP), the lead investor in Springbok’s seed round, also led the Series A funding. Additional participants included the National Basketball Association, Cartan Capital, and Boston Global, along with other strategic investors. Pat Eilers, managing partner and founder of TEP, highlighted that Springbok’s recent FDA clearance is a significant achievement. It validates the technology’s value and “opens up exciting commercial opportunities in healthcare, including visibility to reimbursement.” Eilers added that this advancement holds potential benefits for athletes of all levels, as well as the broader health and wellness of the general public. The funding will support Springbok Analytics’ reach and continued innovation, according to co-founder and chief scientific officer Silvia Blemker.
“I’m incredibly proud of our progress and excited about the opportunities ahead to advance muscle research, improve patient outcomes and empower human performance,” Blemker said.
Springbok will also focus on clinical trials and research. Scott Magargee, Springbok Analytics CEO and co-founder, stated, “This investment positions Springbok to become the global leader in precision muscle health analytics. We are committed to pioneering advancements that redefine muscle health and enhance human performance.”
Springbok’s funding arrives as strength training grows in popularity due to its numerous health benefits, including potentially reducing cancer-related deaths. The company’s approach also reflects a shift toward preventive health and bypassing traditional healthcare systems with supplemental testing. Similar market interest is illustrated by Neko Health, a health tech startup co-founded by Spotify founder Daniel Ek, which recently secured $260 million for its non-invasive body scan system and has a waitlist exceeding 100,000 individuals as it prepares for its U.S. launch.
